GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today successful results from studies of the NOX 1 and 4 inhibitor, GKT137831, in experimental models of liver fibrosis. The data, published jointly with Professor David Brenner, M.D., Dean, School of Medicine, University of California San Diego online in Hepatology (DOI: 10.1002/hep.25938), demonstrates the specificity of GKT137831 and its ability to attenuate development of fibrosis in the liver and production of reactive oxygen species (ROS) in two models of disease, as well as inhibiting messenger RNA expression of fibrotic and NOX genes.
